Lonza Group
Address: Munchensteinerstrasse 38, Basel, CH-4002Social Media
Facebook : https://www.facebook.com/LonzaGroupAGAbout Us
Lonza is an international group of companies involved in research and custom manufacture of API's, High Potency API's, proteins/peptides,vaccines,plasmid DNA, recombinant proteins, and monoclonal antibodies.
From pre-clinical to commercial supply with industry leading processes and a broad technology platform enables your product to reach its full potential.
Sectors
- Collaborations & Partnerships- R&D
- Collaborations & Partnerships-Manufacture
- Collaborations & Partnerships-Services
- Contract Research & Development
- Contract Manufacturing
- Proprietary Research & Manufacture
- Drug Delivery
- Gene/RNA Delivery Technology
Categories
- Finished Dosage
- Active Pharmaceutical Ingredients
- Drug Delivery Technology
- Small Molecule Synthesis
- Small Molecules
- Particle Engineering
- Micronisation
- Inhalation Products
- Respiratory Products
- Process Development
- Biotechnology
- Biologics
- BioPharmaceuticals
- Bioanalysis
- High Potency Formulations
- Sterile Formulations
- Viral Based Therapeutics
- Microbial Fermentation
- Cytotoxic Products
- Clinical Trial Manufacturing
- Cell Therapy Products
- Bioprocess Development
- Lipid Nanoparticles (LNPs)
- Nanoparticles
- Gene Vectors
- Viral Vectors
- Gene Therapy
- Stem Cells
- Bioassay Development
- Bio Process Technologies
- Proteins
- Peptides
- RNA based Products
- Messenger RNA
- DNA based Medicines
- Antibodies-monoclonals
- Bioconjugation
- Antibody Drug Conjugates
- Mammalian cell culture manufacturing
- High Potency API's
- Bioprocessing
- Vaccine Manufacturing
- Vaccine Products
- Fill & Finish
Certifications
- GMP- as per ICH Q7a
- GMP-EU-EDQM-Inspected by an EU National Authority
- GMP-USA-FDA-Inspected
- ISO 9001- Quality Management
Key Contacts
Sarah Holland / Global Head of Licensing / info@lonza.comNews
Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
Basel, Switzerland, 22 October 2024 – Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced today a long-term extension of its collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. The extended agreement will expand the dedicated bioconjugation footprint for the customer through the construction of a new bioconjugation suite at Lonza’s Ibex® Biopark in Visp (CH). In addition, Lonza will provide commercial-scale monoclonal antibody (mAb) manufacturing services for a new ADC therapy.
The new Visp bioconjugation suite will occupy approximately 800m2 of manufacturing space and will support the manufacture, handling, and containment of highly-potent modalities. The new suite is expected to be operational in 2027 and will generate approximately 100 new jobs. The customer-dedicated suite further extends Lonza’s relationship with the customer, which already consists of an integrated supply of the highly potent payload, drug-linker, commercial mAb manufacturing, conjugation services, and DP filling for the ADC molecule targeting hard-to-treat cancers.
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
Basel, Switzerland, 20 March 2024 – Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for USD 1.2 billion.
The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity to meet demand for commercial mammalian contract manufacturing from customers with existing commercial products, and molecules currently on the path to commercialization within the Lonza network. The Vacaville (US) facility currently has a total bioreactor capacity of around 330,000 liters, making it one of the largest biologics manufacturing sites in the world by volume. Under the agreement, approximately 750 Genentech employees at the Vacaville (US) facility will be offered employment by Lonza.
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
Boston, US and Basel, Switzerland, 26 June 2023 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.
Lonza to expand ADC offerings with buy of Synaffix
Swiss contract development and manufacturing organization (CDMO) Lonza today announced it has acquired Dutch biotech company Synaffix, which is focused on commercializing its clinical-stage technology platform for the development of antibody-drug conjugate (ADCs).
Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering
Lonza entered into two new collaborations with McSAF and Cristal Therapeutics to expand its bioconjugates offering.
Lonza Completes Expansion to Solid Form Services Facility at Oregon Site
Basel, Switzerland, 16 January 2023 - Lonza today announces the completion of a planned expansion to its Solid Form Services (SFS) offering for small molecule drugs. The expanded facility in Bend, Oregon (US) became fully operational in Q4 2022, enhancing Lonza's capabilities in meeting accelerated timelines for increasingly complex molecules. The expanded facility includes remodeled and dedicated laboratory space which is primarily being used to support biotech and midsize pharma companies in developing early-stage compounds. It can support all aspects of solid form screening and characterization of small molecule APIs, alongside selection and early crystallization process development. Effective screening and selection are critical for early-stage and late-stage development to reduce risk and strengthen intellectual property claims.
Lonza’s API manufacturing facility expansion in China enters commercial operation
Swiss contract development and manufacturing organization (CDMO) Lonza today announced the start of new mid-scale manufacturing assets at its active pharmaceutical ingredients (API) manufacturing center in Nansha, China.
Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine
Basel, Switzerland, 1 November 2022 – Lonza, a preferred partner to the pharmaceutical, biotech and nutraceutical markets, has launched an innovative new capsule solution for intestinal (enteric) drug delivery. The Capsugel® Enprotect™ capsule does not disintegrate during stomach transit and only releases its contents in the intestine. Capsugel® Enprotect™ capsules significantly simplify the drug product manufacturing process by mitigating the need for additional capsule coating or sealing.
Lonza and Touchlight collaborate on end-to-end mRNA offering
Basel, Switzerland and Hampton, UK, 6 September 2022 – Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, today announced a collaboration with Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution. Through this collaboration, Lonza will have the ability to integrate an additional, differentiated source of DNA in its end-to-end offering to customers developing messenger RNA (mRNA) therapeutics and vaccines, while Touchlight can widen the channels through which customers can gain access to its novel doggybone DNA (dbDNA) technology.
Lonza Joins GENEGUT Project to Develop Capsule Delivery Solution
Four-year project aims to develop an innovative Crohn's disease treatment based on RNA and targeted delivery.
Two Cell and Gene Therapies Manufactured at Lonza Houston Reach US FDA Approval
Basel, Switzerland, Thursday 6 October 2022 – Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutrition industries, today announced that two additional cell and gene therapies manufactured at its Houston (US) site have reached commercial approval in Q3 2022. ZYNTEGLO®, for the treatment of transfusion-dependent beta-thalassemia; and SKYSONA®, for the treatment of early, active cerebral adrenoleukodystrophy, are both manufactured by bluebird bio of Somerville, Massachusetts and were approved in August and September, respectively. These regulatory approvals represent the second and third cell and gene therapy commercial approvals supported by Lonza’s Houston (US) facility.
Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH)
The investment will enable the company to provide customers with a complete and integrated end-to-end solution that includes commercial drug product manufacturing for large-scale market supply. The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026.
Oasmia Signs Manufacturing Agreement with Lonza for Ovarian Cancer Drug Candidate Cantrixil
Lonza delivers CHF 5.4 billion sales in 2021
Lonza has reported sales of CHF 5.4 billion, growing 20% AER (20% CER) and CHF 1.7 billion CORE EBITDA, resulting in a margin of 30.8%.
Lonza and Bioqube Ventures Sign a Framework Agreement
Basel, Switzerland, 30 November 2021 – Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, today announced a framework agreement covering a strategic collaboration for the development and manufacturing of biologics and small molecules.
Lonza and Moderna Enter to Double Drug Substance Production for COVID-19 Vaccine in Visp
- New agreement for three further production lines at Lonza’s site in Visp, Switzerland
- Additional production lines will come online sequentially
- All three are expected to be operational in the earlier part of 2022
Basel, Switzerland, 29 April 2021 – Lonza today announced the expansion of its collaboration with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to manufacture the drug substance for the COVID-19 Vaccine Moderna.
The expanded collaboration provides for the installation of three additional drug substance manufacturing lines at Lonza’s Visp (CH) site. This will double the existing drug substance production for COVID-19 Vaccine Moderna at the site.
In May 2020, Lonza and Moderna announced a 10-year strategic collaboration agreement to enable the manufacture of Moderna’s COVID-19 vaccine and additional Moderna products in the future. Since then, Lonza has installed three production lines at its Visp (CH) site and one further production line in Portsmouth (US). Production in Visp (CH) commenced within eight months of the initial agreement.
Lonza Completes Divestment of Sites to NextPharma
“The strategic divestment of our Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies. In this context, as we close the divestment process, we are confident that NextPharma is well placed to develop and grow both sites to their full potential. We wish to thank the leadership teams and employees at the Ploermel and Edinburgh sites for their continuing dedication and professionalism during the transition period.”
Lonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates
Basel, Switzerland, 2 December 2020 – Lonza today announced a long-term, strategic collaboration for bioconjugation with a global biopharma company. Under the terms of the agreement, Lonza will construct two new customer-dedicated conjugation suites for the commercialization of antibody-drug conjugates (ADCs) at its Visp (CH) site.
As part of Lonza’s Ibex® Dedicate model, a technology-agnostic supply solution that helps reduce time to market and control investment risk, two bioconjugation suites totaling 1500m2 of active manufacturing space will be built out within a pre-existing shell. The new suites will also benefit from established quality control (QC) labs, logistics and other central services, allowing for faster ramp-up times, assured delivery and high performance.
The high throughput bioconjugation suites will be capable of handling highly-potent materials for cancer therapies and will initially manufacture two therapies. The new dedicated facility will employ around 200 staff, with operations expected to start from the end of 2022.
ADC’s are bioconjugates and represent an innovative therapeutic modality that is growing rapidly and providing effective therapies to patients with reduced side effects. ADC’s usually combine an antibody with a highly-potent payload (via a linker molecule) to target cancer cells. The antibody serves as the delivery method to target the toxic drug precisely to cancer cells, limiting toxicity to healthy cells.
Lonza has developed the specific expertise and technology to de-risk the development and manufacturing of bioconjugates and now supports the majority of commercially approved ADCs. In addition, Lonza also offers all elements of a complex supply chain, including manufacturing of biomolecule, synthetic payload, linker and subsequent conjugation at a single site.
Lonza Expands Highly Potent Drug Product Development and Manufacturing Capabilities
Tampa, USA, 18 November 2020 – Lonza has announced additional investments in its oral drug product development and manufacturing capabilities at its Tampa FL site. Capability for formulation development has been enhanced with the upgrade of drug product development laboratories for highly potent material handling. Dry granulation processing has been expanded and standardized with the addition of Gerteis roller compaction equipment. The new roller compactor will be equipped with high containment and adds to Lonza’s integrated highly potent API (HPAPI) value chain across drug substance, particle engineering and specialized drug product.
The containment capability of the new roller compaction unit complements Lonza’s leading capabilities in HPAPI processing across its site network in the US and Europe. The Visp, Switzerland site has one of the world’s largest capacity for HPAPI development and manufacturing. Contained particle engineering, using either jet milling or spray dry processing, and specialized oral solid or parenteral drug product capabilities are also available within the network.
Lonza has invested more than $15M to expand and upgrade the Tampa site capabilities over the last two years. The new roller compaction equipment complements previously made HPAPI processing investments inclusive of a new sampling and dispensing suite, a dedicated suite for product development, and two new product manufacturing suites.
Lonza Announces Agreement to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination
The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19
- cGMP manufacturing of the two long-acting antibodies to begin in H1 2021 at Lonza's Portsmouth, NH (USA) site
Quote from Jean-Christophe Hyvert, Chief Commercial Officer, Lonza:
"Given the threats posed from the ongoing COVID-19 pandemic, advancing options for prevention and treatment are of crucial importance. Our team is extremely motivated to welcome AstraZeneca as one of the first projects in our new mid-scale facility in Portsmouth, NH. The new facility will provide AstraZeneca with the flexibility and the speed needed to manufacture AZD7442 on accelerated timelines."
Basel, Switzerland, 30 October 2020 – Lonza announced today that the company has signed an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of COVID-19. AZD7442 is currently in Phase I clinical studies and AstraZeneca plans to advance the LAAB combination into Phase 3 trials in the coming weeks.
The agreement enables AstraZeneca to leverage Lonza's extensive antibody manufacturing expertise, as well as QC testing, regulatory competence, and experience with accelerated manufacturing campaigns.
Under the terms of the agreement, Lonza will manufacture drug substance (DS) for AZD7442 at Lonza's facilities in Portsmouth (US). Operations are expected to start in H1 2021.
AstraZeneca will be one of the first companies to access Lonza's new mid-scale facilities in Portsmouth, NH (USA). With operations starting later this year, the new hybrid facility combines the cost efficiencies of mid-scale stainless steel bioreactors with disposable downstream technology for flexibility and speed. Automation and process analytic technology also open up the possibilities for real-time data sharing and transparency.
Lonza Expands Its Capsule Manufacturing Capacity
- Investment of CHF85m will expand capsule manufacturing capacity by 30 billion capsules annually
- The new expansion involves eight global Lonza sites
- The investment aims to address the increasing global demand for capsules
Lonza Expands Microbial Capacity to support Servier
- New mid-scale microbial facility to support Servier with active pharmaceutical ingredient (API) for acute lymphoblastic leukemia (ALL) therapies
- Sixth facility to be housed in Lonza’s new biopark in Visp, Switzerland, currently under construction
- Operational in the second half of 2022, 100 new staff to be recruited
Lonza and Chr. Hansen in Joint Venture to Accelerate Momentum in Microbiome
Copenhagen (DK) and Basel (CH), 2 April 2019 – Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, have signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The joint venture will be a 50/50 controlled legal entity that will operate from its headquarters in Basel (CH) and have production facilities in Denmark and Switzerland.
Emerald Health Pharmaceuticals and Lonza Announce Agreement for Manufacturing of Novel Cannabinoid-Derived Drug Candidate
San Diego, CA (USA) and Basel (CH) 13 February 2019 – Emerald Health Pharmaceuticals and Lonza have announced an agreement for the large-scale manufacturing of a new synthetic derivative of cannabidiol (CBD) and its oral drug product for the treatment of multiple sclerosis (MS) and systemic scleroderma, also known as systemic sclerosis (SSc). Under the terms of the agreement, Lonza Pharma & Biotech will synthesize the active pharmaceutical ingredient (API) / drug substance (VCE-004.8) and develop the drug product (EHP-101) as liquid-filled capsules.
Lonza Collaborates with Takeda to Bring Cancer Treatment to Patients
Basel, Switzerland, 11 January 2019 – Lonza today announced another major milestone in its multiproduct partnership with Takeda. Takeda Pharmaceutical Company Limited announced in November 2018 that the European Commission (EC) granted marketing authorization for ALUNBRIG (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NLSC) previously treated with crizotinib.
Lonza Completes Acquisition of Capsugel to Create Leading Integrated Solutions Provider
Lonza to buy Capsugel for $5.5bn, no site divestitures planned
Lonza says it is negotiating deal to buy Capsugel
Lonza opens formulation development and testing lab
Lonza Reports Best First Half in History with Continued Strong Momentum
Lonza Reports Strong Sales and Profit Growth in 2015
Lonza Delivers Strong Results Following Continuing Success of Transformation Efforts----
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com